Suppr超能文献

芬苯达唑代谢物在绵羊体内的胆汁分泌及肝肠循环

Biliary secretion and enterohepatic recycling of fenbendazole metabolites in sheep.

作者信息

Hennessy D R, Steel J W, Prichard R K

机构信息

CSIRO Division of Animal Health, McMaster Laboratory, Glebe, NSW, Australia.

出版信息

J Vet Pharmacol Ther. 1993 Jun;16(2):132-40. doi: 10.1111/j.1365-2885.1993.tb00157.x.

Abstract

Fenbendazole (FBZ) was administered intraruminally at 5.0 mg/kg, containing a trace of [14C]-FBZ, to sheep fitted with a permanent bile duct cannula and the behaviour of FBZ and its metabolites examined in bile and plasma. Of the administered radiolabelled dose, 47% was secreted in bile of which 34% was accounted for as conjugated and 4% as unconjugated (free) metabolites. Hydroxylated oxfendazole (OH.OFZ) was the major biliary metabolite contributing 66%, and hydroxy-FBZ (OH.FBZ) 27%, of the total metabolites characterized. Small amounts of OFZ and hydroxy FBZ sulphone (OH.FBZ.SO2) were also present in bile. The rapid appearance of OH.OFZ in bile, even before maximum concentrations of OFZ occurred in plasma, indicated that sulphoxidation and hydroxylation was the major route of FBZ metabolism. Following intraduodenal infusion of free biliary metabolites, FBZ and its metabolites rapidly appeared in bile indicating absorption from the small intestine. When conjugated metabolites were infused they continued to appear in bile for a further 15-20 h after cessation of infusion indicating that absorption of hydroxylated metabolites occurred largely after bacterial deconjugation in the large intestine. Approximately 40% of biliary metabolites were estimated to undergo enterohepatic reabsorption but they contributed minimally to the metabolite content in plasma. It is suggested that during the process of recycling-biliary metabolites make substantial contact with parasites in the mucosa of the small and large intestine thereby contributing to the anti-helminthic activity of FBZ.

摘要

将含有微量[14C] - 芬苯达唑(FBZ)的芬苯达唑以5.0毫克/千克的剂量经瘤胃内给药给安装有永久性胆管插管的绵羊,并检测FBZ及其代谢产物在胆汁和血浆中的行为。在所给予的放射性标记剂量中,47%分泌到胆汁中,其中34%为结合代谢产物,4%为未结合(游离)代谢产物。羟基奥芬达唑(OH.OFZ)是主要的胆汁代谢产物,占已鉴定出的总代谢产物的66%,羟基 - FBZ(OH.FBZ)占27%。胆汁中也存在少量的奥芬达唑和羟基FBZ砜(OH.FBZ.SO2)。即使在血浆中奥芬达唑尚未达到最大浓度之前,OH.OFZ就在胆汁中迅速出现,这表明硫氧化和羟基化是FBZ代谢的主要途径。在十二指肠内输注游离胆汁代谢产物后,FBZ及其代谢产物迅速出现在胆汁中,表明从小肠吸收。当输注结合代谢产物时,在输注停止后它们在胆汁中继续出现15 - 20小时,这表明羟基化代谢产物的吸收主要发生在大肠中细菌去结合之后。估计约40%的胆汁代谢产物会进行肝肠循环重吸收,但它们对血浆中代谢产物含量的贡献极小。有人认为,在循环过程中,胆汁代谢产物与小肠和大肠黏膜中的寄生虫大量接触,从而有助于FBZ的抗蠕虫活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验